Vical Incorporated  

(Public, NASDAQ:VICL)   Watch this stock  
Find more results for VICL
4.02
+0.22 (5.79%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.75 - 4.07
52 week 2.81 - 15.50
Open 3.75
Vol / Avg. 133,965.00/49,162.00
Mkt cap 391.33M
P/E     -
Div/yield     -
EPS -0.09
Shares 9.20M
Beta 1.96
Inst. own 304%
Jul 28, 2016
Q2 2016 Vical Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 9, 2016
Q1 2016 Vical Inc Earnings Call
May 9, 2016
Q1 2016 Vical Inc Earnings Release
Mar 16, 2016
Vical Inc at ROTH Conference
Mar 14, 2016
Q4 2015 Vical Inc Earnings Call
Mar 14, 2016
Q4 2015 Vical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -52.63% -44.10%
Operating margin -54.52% -44.89%
EBITD margin - -39.36%
Return on average assets -20.01% -17.12%
Return on average equity -21.90% -18.99%
Employees 69 -
CDP Score - -

Address

10390 Pacific Center Ct
SAN DIEGO, CA 92121-4340
United States - Map
+1-858-6461100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Officers and directors

R. Gordon Douglas M.D. Independent Chairman of the Board
Age: 80
Bio & Compensation  - Reuters
Vijay B. Samant President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Anthony Alan Ramos Chief Accounting Officer, Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Mammen P. Mammen Jr. Vice President - Clinical Vaccines
Age: 51
Bio & Compensation  - Reuters
Larry R. Smith PhD Vice President - Vaccine Research
Age: 54
Bio & Compensation  - Reuters
Thomas E. Shenk Ph.D. Director
Age: 66
Bio & Compensation  - Reuters
Richard M. Beleson Independent Director
Age: 61
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 64
Bio & Compensation  - Reuters
Robert C. Merton Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
George J. Morrow Independent Director
Age: 64
Bio & Compensation  - Reuters